Acadian Asset Management LLC Increases Position in Emergent Biosolutions Inc. $EBS

Acadian Asset Management LLC boosted its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 17.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 974,590 shares of the biopharmaceutical company’s stock after purchasing an additional 141,274 shares during the quarter. Acadian Asset Management LLC owned about 1.80% of Emergent Biosolutions worth $6,216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Millennium Management LLC boosted its stake in Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after acquiring an additional 1,020,582 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Emergent Biosolutions by 7.5% during the 1st quarter. American Century Companies Inc. now owns 2,297,621 shares of the biopharmaceutical company’s stock valued at $11,166,000 after purchasing an additional 159,909 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Emergent Biosolutions by 12.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after purchasing an additional 121,583 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Emergent Biosolutions by 5.9% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 986,673 shares of the biopharmaceutical company’s stock worth $6,295,000 after buying an additional 55,046 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. grew its stake in Emergent Biosolutions by 198.9% during the 1st quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock worth $3,050,000 after buying an additional 417,671 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, November 7th. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 3rd. Finally, Wall Street Zen upgraded Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Emergent Biosolutions currently has an average rating of “Hold” and an average target price of $15.00.

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 7,086 shares of Emergent Biosolutions stock in a transaction on Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the sale, the director owned 71,799 shares in the company, valued at $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Coleen Glessner sold 30,608 shares of the business’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total value of $306,080.00. Following the completion of the sale, the executive vice president directly owned 144,319 shares in the company, valued at approximately $1,443,190. The trade was a 17.50% decrease in their position. The SEC filing for this sale provides additional information. 1.20% of the stock is owned by insiders.

Emergent Biosolutions Trading Down 0.8%

Shares of NYSE:EBS opened at $10.80 on Thursday. The business’s 50 day moving average price is $9.26 and its 200-day moving average price is $7.72. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $13.41. The firm has a market capitalization of $566.95 million, a price-to-earnings ratio of 8.30 and a beta of 2.05. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter. The firm had revenue of $222.50 million for the quarter. Emergent Biosolutions had a return on equity of 21.43% and a net margin of 9.62%. Emergent Biosolutions has set its FY 2023 guidance at EPS. On average, equities research analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.